Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Thomas Martin; Meletios-Athanasios Dimopoulos; Joseph Mikhael; Kwee Yong; Marcelo Capra; Thierry Facon; Roman Hajek; Ivan Špička; Ross Baker; Kihyun Kim; Gracia Martinez; Chang-Ki Min; Ludek Pour; Xavier Leleu; Albert Oriol; Youngil Koh; Kenshi Suzuki; France Casca; Sandrine Macé; Marie-Laure Risse; Philippe Moreau

doi:10.1038/s41408-023-00923-6

Back

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Journal article

Open access

Peer reviewed

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, …

Blood Cancer Journal, Vol.13, 152

2023

DOI: https://doi.org/10.1038/s41408-023-00923-6

Files and links (1)

pdf

Correction Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma updated results from IKEMA, a randomized Phase 3 study (Blood Cancer Journal, (2023), 13, 1, (72), 10.1038s41408-023-00797385.29 kBDownload View

Correction (Corrected version of record)CC BY V4.0, Open Access

Abstract

Correction to: Blood Cancer Journal https://doi.org/10.1038/s41408-023-00797-8, published online 09 May 2023 In the sentence beginning ‘Isa is approved in multiple countries...’ in ‘Introduction’, the term ‘treatment lines’ should have read ‘therapies’. The full text is as follows. Isa is approved in multiple countries in combination with pomalidomide and low-dose dexamethasone for patients with RRMM after ≥2 prior therapies, based on the results of the randomized Phase 3 ICARIA-MM study. The original article has been corrected.

Details

Title: Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Authors/Creators: Thomas Martin
Meletios-Athanasios Dimopoulos
Joseph Mikhael - Translational Genomics Research Institute
Kwee Yong - University College Hospital
Marcelo Capra - Hospital Mãe de Deus
Thierry Facon - Lille’s Cardiology Hospital
Roman Hajek - University of Ostrava
Ivan Špička - Charles University
Ross Baker - Murdoch University, Centre for Molecular Medicine and Innovative Therapeutics
Kihyun Kim - Sungkyunkwan University
Gracia Martinez - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Chang-Ki Min - Catholic University of Korea
Ludek Pour - University Hospital Brno
Xavier Leleu - Inserm
Albert Oriol - Institut Català d'Oncologia
Youngil Koh - Seoul National University Hospital
Kenshi Suzuki - Japanese Red Cross Medical Center
France Casca
Sandrine Macé - Sanofi (France)
Marie-Laure Risse
Philippe Moreau
Publication Details: Blood Cancer Journal, Vol.13, 152
Publisher: Nature Publishing Group
Identifiers: 991005608870107891
Copyright: © The Author(s) 2023
Murdoch Affiliation: Centre for Molecular Medicine and Innovative Therapeutics
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

3 File views/ downloads

64 Record Views

6 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.108 Molecular & Cell Biology - Cancer & Development; 1.108.2215 Hippo Pathway
Web Of Science research areas: Hematology; Oncology
ESI research areas: Clinical Medicine